PTO/SB/21 (09-04 Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/511.463 Filing Date TRANSMITTAL October 14, 2004 First Named Inventor **FORM** Yuval Simha Landschaft Art Unit Examiner Name (to be used for all correspondence after initial filing) Attorney Docket Number RO0908US (#90568) Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Drawing(s) Fee Transmittal Form Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Petition to Convert to a **Proprietary Information** After Final Provisional Application Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify Terminal Disclaimer below): **Extension of Time Request**

return postcard receipt Request for Refund **Express Abandonment Request** CD, Number of CD(s)_ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name D. Peter Hochberg Co., L.P.A. Signature Printed name D. Peter Hochberg Reg. No. Date 2006 24,603

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Sean Mellino

Date

01/31/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF MAILING

Mereby certify that this document is being deposited with the United States Postal Service as First Class mail in an envelope Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date noted below:

Date: 1/31/06

Sean Melling

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Yuval Simha Landschaft

Serial No.

10/511,463 (Conf. No. 9282)

Filing Date

October 14, 2004

Examiner

exammer :

Group Art Unit:

Title

A PLATFORM FOR TRANSDERMAL

FORMULATIONS (PTF)

Attorney File:

RO0908US (#90568)

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97

Mail Stop Amendment Commissioner for Patents P O Box 1450 Alexandria, Virginia, 22313-1450

Dear Sir,

Under the provision of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant would like to call the Examiner's attention to the reference listed on the attached Form PTO-1449, which has been cited in the prosecution of the corresponding German application upon which the present application claims priority. The reference is a U.S. patent reference, and so a copy is not enclosed herewith.

In accordance with 37 C.R.F. 1.97(b)(3), and as this Information Disclosure Statement is being filed before the issuance of a first Official action on the merits of the application, no government fee or statement under 37 C.F.R. 1.97(e) is required.

In accordance with 37 C.F.R. 1.97(g) and 37 C.F.R. 1.97(h), filing of this Information disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 34 C.F.R. 1.56(b).

The Examiner is requested to make the attached references of record and to consider these references along with such other references deemed pertinent as a result of the Examiner's own independent search and examination.

Respectfully submitted,

D. Peter Hochberg Reg. No. 24,603

D. Peter Hochberg Co., L.P.A. 1940 E.6th Street – 6th Floor Cleveland, OH 44114 (216) 771-3800

DPH/sfm

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :

Yuval Simha Landschaft

Serial No.

10/511,463 (Conf. No. 9282)

Filing Date

October 14, 2004

Examiner

Group Art Unit:

Title

A PLATFORM FOR TRANSDERMAL

FORMULATIONS (PTF)

Attorney File:

RO0908US (#90568)

Mail Stop Amendment Commissioner for Patents P O Box 1450 Alexandria, Virginia, 22313-1450

U S PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	
	5,332,577	7/26/94	Gertner, et al.	
Examiner		Date Co	onsidered:	

Examiner:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant